Published in J Mol Biol on October 20, 1989
Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A (1991) 1.97
Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci U S A (1991) 1.94
Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta. Proc Natl Acad Sci U S A (1991) 1.73
Disordered water within a hydrophobic protein cavity visualized by x-ray crystallography. Proc Natl Acad Sci U S A (1999) 1.55
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature (2016) 1.44
Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand. J Exp Med (2000) 1.38
Three-dimensional crystal structure of recombinant murine interferon-beta. EMBO J (1992) 1.23
Determination of solvent content in cavities in IL-1beta using experimentally phased electron density. Proc Natl Acad Sci U S A (2006) 1.11
Refinement of the structure of human basic fibroblast growth factor at 1.6 A resolution and analysis of presumed heparin binding sites by selenate substitution. Protein Sci (1993) 1.08
A review about nothing: are apolar cavities in proteins really empty? Protein Sci (2009) 1.06
Water in the polar and nonpolar cavities of the protein interleukin-1β. J Phys Chem B (2010) 1.05
The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets. Proc Natl Acad Sci U S A (1996) 1.04
Considering protonation as a posttranslational modification regulating protein structure and function. Annu Rev Biophys (2013) 0.98
Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. Biophys J (1996) 0.96
Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem (2012) 0.96
A procedure for the automatic determination of hydrophobic cores in protein structures. Protein Sci (1995) 0.94
Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. Proc Natl Acad Sci U S A (1991) 0.94
β-Bulge triggers route-switching on the functional landscape of interleukin-1β. Proc Natl Acad Sci U S A (2012) 0.93
Young Investigator Award Lecture. Structures of larger proteins, protein-ligand and protein-DNA complexes by multidimensional heteronuclear NMR. Protein Sci (1994) 0.88
Correlation between the 1.6 A crystal structure and mutational analysis of keratinocyte growth factor. Protein Sci (1998) 0.87
The liverwort contains a lectin that is structurally and evolutionary related to the monocot mannose-binding lectins. Plant Physiol (2002) 0.87
Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor. Proc Natl Acad Sci U S A (1991) 0.85
Molecular dynamics free energy calculations to assess the possibility of water existence in protein nonpolar cavities. Biophys J (2010) 0.79
Altered backbone and side-chain interactions result in route heterogeneity during the folding of interleukin-1β (IL-1β). Biophys J (2013) 0.79
ATP-Induced Inflammasome Activation and Pyroptosis Is Regulated by AMP-Activated Protein Kinase in Macrophages. Front Immunol (2016) 0.79
Structure and function of interleukin-1, based on crystallographic and modeling studies. Biophys J (1992) 0.78
Comparative analysis of receptor binding by chicken and human interleukin-1β. J Mol Model (2010) 0.77
Arg-27, Arg-127 and Arg-155 in the beta-trefoil protein barley alpha-amylase/subtilisin inhibitor are interface residues in the complex with barley alpha-amylase 2. Biochem J (1995) 0.76
The response of Greek key proteins to changes in connectivity depends on the nature of their secondary structure. J Mol Biol (2015) 0.75
Macromolecular Crystallographic Information File. Methods Enzymol (1997) 11.94
Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature (1997) 4.55
Effect of ongoing treatment of amblyopia on surgical outcome in esotropia. J Pediatr Ophthalmol Strabismus (1997) 2.81
Crystal structure of the biphenyl-cleaving extradiol dioxygenase from a PCB-degrading pseudomonad. Science (1995) 2.68
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J Biol Chem (1999) 2.34
NH---S hydrogen bonds in Peptococcus aerogenes ferredoxin, Clostridium pasteurianum rubredoxin, and Chromatium high potential iron protein. Proc Natl Acad Sci U S A (1975) 1.91
Cation binding to the integrin CD11b I domain and activation model assessment. Structure (1998) 1.90
Water structure in a protein crystal: rubredoxin at 1.2 A resolution. J Mol Biol (1978) 1.89
Crystallographic refinement of rubredoxin at 1 x 2 A degrees resolution. J Mol Biol (1980) 1.85
Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J (1997) 1.83
The structure of a non-heme iron protein: rubredoxin at 1.5 Angstrom resolution. Cold Spring Harb Symp Quant Biol (1972) 1.67
The atomic-resolution structure of human caspase-8, a key activator of apoptosis. Structure (1999) 1.54
Structure of the oxidized form of a flavodoxin at 2.5-Angstrom resolution: resolution of the phase ambiguity by anomalous scattering. Proc Natl Acad Sci U S A (1972) 1.47
Comparison of the crystal structures of a flavodoxin in its three oxidation states at cryogenic temperatures. J Mol Biol (1991) 1.44
The structure of rubredoxin at 1.2 A resolution. J Mol Biol (1979) 1.38
Crystal structure of ErmC', an rRNA methyltransferase which mediates antibiotic resistance in bacteria. Biochemistry (1998) 1.37
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem (1998) 1.29
The binding of riboflavin-5'-phosphate in a flavoprotein: flavodoxin at 2.0-Angstrom resolution. Proc Natl Acad Sci U S A (1973) 1.26
Intestinal secretion of erythromycin base. J Pharm Sci (1976) 1.24
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1996) 1.24
Separate receptors mediating the positive inotropic and chronotropic effect of histamine in guinea-pig atria. Eur J Pharmacol (1975) 1.21
Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J Mol Biol (1999) 1.21
Crystal structure of Cd,Zn metallothionein. Science (1986) 1.15
Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1994) 1.09
Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. J Biol Chem (1992) 1.08
The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism. J Biol Chem (2001) 1.08
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. J Med Chem (1997) 1.06
The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J Biol Chem (1993) 1.01
Kinetic and crystallographic studies of Escherichia coli UDP-N-acetylmuramate:L-alanine ligase. Protein Sci (1996) 1.00
Thermal stability determinants of chicken egg-white lysozyme core mutants: hydrophobicity, packing volume, and conserved buried water molecules. Protein Sci (1995) 1.00
Electrophysiologic properties of propoxyphene and norpropoxyphene in canine cardiac conducting tissues in vitro and in vivo. Toxicol Appl Pharmacol (1979) 0.96
The crystal structure of a lysine 49 phospholipase A2 from the venom of the cottonmouth snake at 2.0-A resolution. J Biol Chem (1990) 0.94
First look at RNA in L-configuration. Acta Crystallogr D Biol Crystallogr (2003) 0.93
A23187: a calcium ionophore that directly increases cardiac contractility (38704). Proc Soc Exp Biol Med (1975) 0.91
A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochem Biophys Res Commun (1999) 0.87
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors. J Med Chem (1996) 0.86
Calcium fluxes and contractility in isolated guinea pig atrium: effect of A23187. Am J Physiol (1978) 0.85
Crystallographic analyses of an active HIV-1 ribonuclease H domain show structural features that distinguish it from the inactive form. Acta Crystallogr D Biol Crystallogr (1993) 0.85
Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci (1996) 0.84
Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand. J Med Chem (1997) 0.84
Removal of salt from a salt-induced protein crystal without cross-linking. Preliminary examination of "desalted" crystals of phosphoglucomutase by X-ray crystallography at low temperature. Biochemistry (1991) 0.83
Antihypertensive effects of fluoxetine and L-5-hydroxytryptophan in rats. Life Sci (1979) 0.82
Crystallization of microsomal triglyceride transfer protein from bovine liver. Acta Crystallogr D Biol Crystallogr (1996) 0.81
Overview of phasing by isomorphous replacement. Methods Enzymol (1985) 0.81
Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors. J Med Chem (1996) 0.81
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors. J Med Chem (1995) 0.81
Structures and comparison of the Y98H (2.0 A) and Y98W (1.5 A) mutants of flavodoxin (Desulfovibrio vulgaris). Acta Crystallogr D Biol Crystallogr (2001) 0.80
Molecular, biological, and preliminary structural analysis of recombinant bryodin 1, a ribosome-inactivating protein from the plant Bryonia dioica. Biochemistry (1997) 0.79
[Color Doppler imaging of central retinal artery in retinopathy of prematurity]. Harefuah (2000) 0.79
Crystallization and preliminary X-ray analysis of CTLA-4 (CD152) membrane-external domain. Acta Crystallogr D Biol Crystallogr (2000) 0.78
Crystal structure of Cd,Zn metallothionein. Experientia Suppl (1987) 0.78
Hemodynamic and electrocardiographic effects of fluoxetine and its major metabolite, norfluoxetine, in anesthetized dogs. Toxicol Appl Pharmacol (1986) 0.77
Structure of secreted aspartic proteinases from Candida. Implications for the design of antifungal agents. Adv Exp Med Biol (1998) 0.77
Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors. J Med Chem (1995) 0.76
Structural basis of the thrombin selectivity of a ligand that contains the constrained arginine mimic (2S)-2-amino-(3S)-3-(1-carbamimidoyl- piperidin-3-yl)-propanoic acid at P1. J Med Chem (2000) 0.76
X-ray Crystallography Techniques. Science (1975) 0.75
Sequence of rubredoxin by x-ray diffraction. J Mol Biol (1973) 0.75
Recombinant DNA technology and crystallography. A new alliance in unraveling protein structure-function relationships. Bioprocess Technol (1991) 0.75
Crystallization of the NAD-dependent malic enzyme from the parasitic nematode Ascaris suum. J Mol Biol (1992) 0.75
Initial crystallographic analysis of a recombinant human interleukin-1 receptor antagonist protein. Acta Crystallogr D Biol Crystallogr (1994) 0.75
Flavodoxin from the sulfate reducing bacterium Desulfovibrio vulgaris. Its structure at 2.5 A resolution. Z Naturforsch B (1972) 0.75
Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones. Bioorg Med Chem Lett (1998) 0.75
Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications. Bioorg Med Chem Lett (1998) 0.75
Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors. J Med Chem (2000) 0.75
Structure and conformation of 4-peroxycyclophosphamide. A cytotoxic oxidation product of cyclophosphamide. J Am Chem Soc (1974) 0.75
Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure. J Med Chem (1995) 0.75
Soybean trypsin inhibitor. An IL-1-like protein? Agents Actions (1989) 0.75
Programs for phasing by entropy maximization as implemented in Xtal3.2: a crystallographic software system. Acta Crystallogr D Biol Crystallogr (1993) 0.75
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. J Med Chem (1995) 0.75
Potent and selective bicyclic lactam inhibitors of thrombin: Part 3: P1' modifications. Bioorg Med Chem Lett (1999) 0.75
Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers. Drug Des Discov (1994) 0.75
Resolution of microheterogeneity associated with recombinant HIV-1 heterodimeric reverse transcriptase. Protein Expr Purif (1992) 0.75
Crystallization and preliminary crystallographic analysis of E. coli uridine 5'-diphospho-N-acetylenolpyruvylglucosamine reductase in two new crystal forms. Acta Crystallogr D Biol Crystallogr (1996) 0.75
Protein crystal growth aboard the U.S. space shuttle flights STS-31 and STS-32. Adv Space Res (1992) 0.75
Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity. J Med Chem (1998) 0.75